Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma

Karun Neupane,1 Ahsan Wahab,2 Adeel Masood,3 Tehniat Faraz,4 Saman Bahram,5 Hamid Ehsan,6 Abdul Hannan,7 Faiz Anwer8 1Department of Internal Medicine, Manipal College of Medical Sciences, Pokhara, Gandaki, Nepal; 2Department of Internal Medicine, Baptist Medical Center South/University of Alabama at...

Full description

Bibliographic Details
Main Authors: Neupane K, Wahab A, Masood A, Faraz T, Bahram S, Ehsan H, Hannan A, Anwer F
Format: Article
Language:English
Published: Dove Medical Press 2021-07-01
Series:Journal of Blood Medicine
Subjects:
hematological malignancy
treatment
safety
ocular toxicity
relapsed and refractory multiple myeloma
Online Access:https://www.dovepress.com/profile-and-management-of-toxicity-of-selinexor-and-belantamab-mafodot-peer-reviewed-fulltext-article-JBM

Internet

https://www.dovepress.com/profile-and-management-of-toxicity-of-selinexor-and-belantamab-mafodot-peer-reviewed-fulltext-article-JBM

Similar Items